These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38937146)

  • 41. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Khanna D; Distler O; Avouac J; Behrens F; Clements PJ; Denton C; Foeldvari I; Giannini E; Huscher D; Kowal-Bielecka O; Lovell D; Matucci-Cerinic M; Mayes M; Merkel PA; Nash P; Opitz CF; Pittrow D; Rubin L; Seibold JR; Steen V; Strand CV; Tugwell PS; Varga J; Zink A; Furst DE; ;
    J Rheumatol; 2009 Oct; 36(10):2356-61. PubMed ID: 19820225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The challenges and controversies of measuring disease activity in systemic sclerosis.
    Ross L; Baron M; Nikpour M
    J Scleroderma Relat Disord; 2018 Jun; 3(2):115-121. PubMed ID: 35382236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
    Distler O; Behrens F; Pittrow D; Huscher D; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Furst DE;
    Arthritis Rheum; 2008 Jun; 59(6):867-75. PubMed ID: 18512721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey.
    Bruni C; Chung L; Hoffmann-Vold AM; Assassi S; Gabrielli A; Khanna D; Bernstein EJ; Distler O;
    Clin Exp Rheumatol; 2022 Oct; 40(10):1951-1955. PubMed ID: 35819810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.
    Fasano S; Riccardi A; Messiniti V; Caramaschi P; Rosato E; Maurer B; Smith V; Siegert E; De Langhe E; Riccieri V; Airó P; Mihai C; Avouac J; Zanatta E; Walker UA; Iannone F; García De la Peña Lefebvre P; Distler JHW; Vacca A; Distler O; Kowal-Bielecka O; Allanore Y; Valentini G
    Ann Rheum Dis; 2019 Dec; 78(12):1681-1685. PubMed ID: 31422354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea.
    García-Romero MT; Tollefson M; Pope E; Brandling-Bennett HA; Paller AS; Keimig E; Arkin L; Wanat KA; Humphrey SR; Werth VP; Oza V; Jacobe H; Fett N; Cordoro KM; Medina-Vera I; Chiu YE
    JAMA Dermatol; 2023 Mar; 159(3):299-307. PubMed ID: 36753150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases.
    Coulter C; Baron M; Pope JE
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):24-30. PubMed ID: 23557780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A rare disease patient-reported outcome measure: revision and validation of the German version of the Systemic Sclerosis Quality of Life Questionnaire (SScQoL) using the Rasch model.
    Kocher A; Ndosi M; Denhaerynck K; Simon M; Dwyer AA; Distler O; Hoeper K; Künzler-Heule P; Redmond AC; Villiger PM; Walker UA; Nicca D
    Orphanet J Rare Dis; 2021 Aug; 16(1):356. PubMed ID: 34372892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.
    Kowal-Bielecka O; Avouac J; Pittrow D; Huscher D; Behrens F; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Strand V; Furst DE; Distler O;
    J Rheumatol; 2010 Jan; 37(1):105-15. PubMed ID: 19955042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Ferreira PL; Genrinho I; Santiago T; Carones A; Mazeda C; Barcelos A; Beirão T; Costa F; Santos I; Couto M; Rato M; Terroso G; Monteiro P
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of disease activity indices using the 28 joint counts in systemic sclerosis.
    Lóránd V; Bálint Z; Komjáti D; Németh B; Minier T; Kumánovics G; Farkas N; Czirják L; Varjú C;
    Rheumatology (Oxford); 2016 Oct; 55(10):1849-58. PubMed ID: 27402873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology.
    Butler EA; Baron M; Fogo AB; Frech T; Ghossein C; Hachulla E; Hoa S; Johnson SR; Khanna D; Mouthon L; Nikpour M; Proudman S; Steen V; Stern E; Varga J; Denton C; Hudson M;
    Arthritis Rheumatol; 2019 Jun; 71(6):964-971. PubMed ID: 30614663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of the Systemic Sclerosis-Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short-Form Development.
    Yu L; Domsic RT; Saketkoo LA; Withey J; Frech TM; Herrick AL; Hummers LK; Shah AA; Denton CP; Khanna D; Pauling JD
    Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1725-1734. PubMed ID: 36214062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.
    Zulian F; Woo P; Athreya BH; Laxer RM; Medsger TA; Lehman TJ; Cerinic MM; Martini G; Ravelli A; Russo R; Cuttica R; de Oliveira SK; Denton CP; Cozzi F; Foeldvari I; Ruperto N
    Arthritis Rheum; 2007 Mar; 57(2):203-12. PubMed ID: 17330294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Patient and Physician Assessments of Gastrointestinal Disease Activity in Systemic Sclerosis.
    Ross L; Proudman S; Walker J; Stevens W; Ferdowsi N; Quinlivan A; Morrisroe K; Baron M; Nikpour M
    J Rheumatol; 2023 Apr; 50(4):519-525. PubMed ID: 36379565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician's Global Assessment of Disease Severity in Systemic Sclerosis.
    Harel D; Hudson M; Iliescu A; Baron M; ; Steele R
    J Rheumatol; 2016 Aug; 43(8):1510-8. PubMed ID: 27307525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS).
    Pope J
    Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S98-111. PubMed ID: 22588774
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.